摘要
目的:探讨曲美他嗪与氯吡格雷联合治疗冠心病心绞痛的效果,并评估其对患者心肌肌钙蛋白I(cTnI)、肌酸激酶同工酶(CK-MB)和氨基末端脑钠肽前体(NT-proBNP)表达的影响。方法:采用随机数字表法对2022年7月至2024年8月就诊于该院的96例冠心病心绞痛患者进行分组,对照组48例患者接受曲美他嗪单药治疗,研究组48例患者接受曲美他嗪联合氯吡格雷治疗。评估并比较两组患者的临床疗效、临床指标和用药安全性,并比较治疗前后实验室指标的变化。结果:(1)研究组患者的总有效率为95.83%(46/48),明显高于对照组的79.17%(38/48),差异有统计学意义(P<0.05)。(2)相较于对照组,研究组患者的心绞痛持续时间较短,心绞痛发作频率较少,心电图ST段下移程度较低,差异均有统计学意义(P<0.05)。(3)与治疗前相比,治疗后两组患者cTnI、CK-MB及NT-proBNP水平显著降低,同时研究组患者上述各项指标水平低于对照组,差异均有统计学意义(P<0.05)。(4)治疗期间,研究组6例患者出现不良反应,不良反应总发生率为12.50%;对照组3例患者出现不良反应,不良反应总发生率为6.25%。两组患者不良反应总发生率的差异无统计学意义(P>0.05)。结论:联合应用曲美他嗪与氯吡格雷治疗冠心病心绞痛患者,不仅能显著提高临床总有效率,改善心绞痛症状和心电图表现,缩短心绞痛持续时间,减少发作频率,还能有效降低心肌损伤和心功能生物标志物水平,显示出良好的治疗效果和安全性。
OBJECTIVE:To probe into the efficacy of trimetazidine combined with clopidogrel in the treatment of angina pectoris in patients with coronary heart disease,and to evaluate its effects on expression of cardiac troponin I(cTnI),creatine kinase isoenzyme(CK-MB),and N-terminal pro-brain natriuretic peptide(NT-proBNP).METHODS:A total of 96 patients with coronary heart disease and angina pectoris admitted into the hospital from Jul.2022 to Aug.2024 were randomly divided into two groups by random number table method.The control group(n=48)received trimetazidine monotherapy;while the study group(n=48)was treated with trimetazidine combined with clopidogrel.The clinical efficacy,clinical indicators and medication safety of two groups were evaluated and compared,and the changes of laboratory indicators before and after treatment were compared.RESULTS:(1)The total effective rate of study group was 95.83%(46/48),significantly higher than 79.17%(38/48)of control group,with statistically significant differences(P<0.05).(2)Compared with the control group,the duration of angina pectoris in study group was shorter,the frequency of angina pectoris was less,and the degree of electrocardiogram ST segment depression was lower,with statistically significant differences(P<0.05).(3)Compared with before treat-ment,the levels of cTnI,CK-MB and NT-proBNP in two groups significantly decreased after treatment,and the levels of the above indicators in study group were lower than those in control group,with statistically significant differences(P<0.05).(4)During the treatment,6 cases of adverse drug reactions occurred in the study group,with an incidence of 12.50%;while 3 cases of adverse drug reactions occurred in the control group,with an incidence of 6.25%.There was no significant difference in the total incidence of adverse drug reactions between two groups(P>0.05).CONCLUSIONS:In patients with coronary heart disease and angina pectoris,trimetazidine combined with clopidogrel can not only significantly improve the total clinical effective rate,improve the symptoms of angina pectoris and electrocardiogram,shorten the duration of angina pectoris,reduce the frequency of attacks,but effectively reduce the levels of myocardial injury and cardiac function biomarkers,showing significant therapeutic effect and safety.
作者
沈建军
王丹
王增悦
张丽娜
孟贺
SHEN Jianjun;WANG Dan;WANG Zengyue;ZHANG Lina;MENG He(Dept.of Laboratory,the 962nd Hospital of the PLA Joint Logistic Support Force,Harbin 150080,China)
出处
《中国医院用药评价与分析》
2025年第7期835-838,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
冠心病
心绞痛
曲美他嗪
氯吡格雷
心功能
用药安全性
Coronary heart disease
Angina pectoris
Trimetazidine
Clopidogrel
Cardiac function
Safety of medication
